Penn spinout Cabaletta Bio’s first funding round includes university investment and it will use the cash to develop T-cell drugs for autoimmune diseases including pemphigus vulgaris.

Lilly Asia Ventures and existing investor Taiho Ventures both contributed to a round for immunotherapy developer Harpoon Therapeutics following a $45m series B last year.

SoftBank Ventures Korea, which previously led a $2.1m seed round for Rael six months ago, has returned to contribute to a $17.5m series A alongside GS Retail Fund.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

University of Minnesota is part of a list of limited partners that provided $150m for Brazil-based venture firm Monashees to close its eighth fund.

Novo invested in liver disease drug developer Mirum Pharmaceuticals as part of the round while Shire acquired an equity stake in the startup through a licensing deal.

UPMC and Cigna Ventures were among the contributors to the first fund raised by healthcare services and software VC firm Health Velocity Capital.

McKesson Ventures and returning investor BlueCross BlueShield Venture Partners took part in a round that will support the cancer data provider's technology capabilities.

Bristol spinout Vitamica has closed a seed round with the backing of University of Bristol Enterprise Fund II and Wyvern Seed Fund.

UCLA spinout Hypothermia Devices graduated from a university-based accelerator in February and is now commercialising body temperature management devices for the medical and athletics markets.